News |

Life Science Analysis: RNA therapeutics are now a clinical reality

After nearly two decades in development, RNA therapeutics are now a clinical reality. 

Shore Capital’s Healthcare Analyst, Tara Raveendran, discusses how the approval of these RNA-based therapeutics marks the start of the next chapter in what has been a rollercoaster ride for this novel drug class.

Tara Raveendran’s article was published in the October 2018 edition of MedNous, and is available to download here.

 

Tara Raveendran

Healthcare Analyst, Research

+44 (0)20 7647 8142

Our website uses necessary cookies in order for it to run. We would also like to use optional analytics cookies to improve the site, by collecting and reporting information on how you use it. These cookies do not directly identify the user and won’t set optional cookies unless they are accepted. For more information on how our site cookies work, please see our Privacy Policy.